Silenor

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Silenor

What is Silenor

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a medication used to treat depression and anxiety. It belongs to a class of drugs called tricyclic antidepressants, but it does not have the same exact properties as them. Doxepin was first approved by the FDA in 1969 for use as an antidepressant and was later approved in 2010 for the treatment of insomnia. It was developed by Pfizer and is available under the brand name Silenor.

Sinequan

is the brand name

image of different drug pills on a surface

Silenor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Silenor Affects Patients

Doxepin is a type of antidepressant that works by decreasing electrical activity in the brain. It can cause antidepressant, sedative, and anticholinergic effects, but at higher doses the anticholinergic and antiadrenergic properties become more prominent. The antidepressant effects of doxepin become noticeable after 2 weeks, while the sedative effects can be seen right away.

How Silenor works in the body

Doxepin works by blocking histamine receptors, which helps to treat skin conditions. Additionally, it works on the central nervous system to increase the activity of norepinephrine and serotonin, which are neurotransmitters. This increases the activity at the post-synaptic neuron receptor sites. Doxepin also desensitizes serotonin 1A receptors and beta-adrenergic receptors. Lastly, it is thought to increase dopamine activity in the frontal cortex.

When to interrupt dosage

The dosage of Silenor is contingent upon the identified condition, including Depression, Involutional, Mental Disorder, Organic and Insomnia. The measure of dosage is contingent upon the technique of application (e.g. Oral or Tablet - Oral) featured in the table beneath.

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Silenor Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Silenor.

Common Silenor Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Silenor Toxicity & Overdose Risk

Taking too much doxepin can cause seizures, irregular heartbeat, unconsciousness, low blood pressure, and depression of the central nervous system. It can also lead to changes in electrocardiogram results and even death. Additionally, doxepin affects fertility in men and women, leading to decreased implantation and litter size, as well as abnormal sperm and reduced sperm motility. There is no evidence that it causes cancer or genetic mutations.

Silenor Novel Uses: Which Conditions Have a Clinical Trial Featuring Silenor?

Currently, 1020 active studies are looking into the potential of Silenor to provide relief from Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

169 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

281 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Silenor Reviews: What are patients saying about Silenor?

5

Patient Review

6/15/2016

Silenor for Chronic Trouble Sleeping

I've been using this treatment for two weeks and it's helped me stay asleep through the night. At first I felt groggy during the day, but that has passed. Now I'm really pleased with how well it works.

5

Patient Review

5/12/2016

Silenor for Chronic Trouble Sleeping

This was very easy to use, and it worked immediately.

5

Patient Review

2/22/2018

Silenor for Chronic Trouble Sleeping

I find that if I eat dinner no later than 6:30 PM and then take Silenor at 10:30 PM, I sleep really well. Before taking this medication, I would average 4 to 5 hours of sleep per night; however, now I'm averaging 7.5 hours of sleep per night.

4.7

Patient Review

3/14/2016

Silenor for Chronic Trouble Sleeping

Before taking Silenor, I was only sleeping for two to four hours per night. This medication doesn't make you fall asleep, but it does help you stay asleep once you do fall asleep. It's been a lifesaver.

4.3

Patient Review

9/22/2014

Silenor for Chronic Trouble Sleeping

I've been using Ambien for a while now, and unfortunately my body became used to it after a few years. Thankfully, my doctor recommended that I also take Silenor in order to combat this problem. So far it's working great!

4.3

Patient Review

10/17/2016

Silenor for Chronic Trouble Sleeping

I love how this treatment helps me sleep, but unfortunately I have to be careful not to use it more than a couple nights in a row or else I get a dry mouth.

2.7

Patient Review

4/28/2018

Silenor for Chronic Trouble Sleeping

This drug helped me sleep at first, but after a few weeks I started experiencing some bad side effects. The worst was memory loss; I would constantly forget things or do something and then completely forget about it. It also made my depression and anxiety much worse. Do not take more than prescribed, as I made this mistake and slept for over 24 hours straight. Would not recommend this drug.

2.3

Patient Review

5/9/2015

Silenor for Chronic Trouble Sleeping

I have been taking this medication for a week now and it keeps me up all night. I would not recommend it to anyone.

2.3

Patient Review

8/29/2016

Silenor for Chronic Trouble Sleeping

Unfortunately, this did not help me fall asleep at all. As a result, I've gotten no sleep and feel pretty terrible.

2.3

Patient Review

12/21/2014

Silenor for Chronic Trouble Sleeping

This medication definitely keeps me awake; however, it also gives me weird and intrusive thoughts. Additionally, I feel like the room temperature is significantly warmer than it actually is.

2

Patient Review

7/24/2018

Silenor for Chronic Trouble Sleeping

This drug was sometimes effective when I took it to sleep, but not always. At $25 a bottle, it was worth trying. However, now that the price has gone up to $100 for a 30 day supply, it's not worth it anymore.

1.7

Patient Review

11/6/2016

Silenor for Chronic Trouble Sleeping

I would not recommend this drug to anyone. It caused me severe depression and crying fits, and did nothing to help my insomnia.

1.7

Patient Review

11/1/2015

Silenor for Chronic Trouble Sleeping

Ambien only helped me sleep for four hours, so I decided to try this treatment. The first night, I woke up after only one hour of sleep. The second night, I took two doses and slept for an extra hour... but that still wasn't enough. This didn't work for me at all.

1.7

Patient Review

11/10/2019

Silenor for Chronic Trouble Sleeping

PSA - I was prescribed doxepin for insomnia and anxiety. After a lower dose was not effective, my Dr. increased the dose. The first night on the increased dose, I slept drove and was arrested for a DUI. I also had significant memory issues during the several months I was prescribed doxepin and which have persisted. Upon discontinuing doxepin, side effects ceased. Take with EXTREME CAUTION

1.7

Patient Review

7/24/2018

Silenor for Chronic Trouble Sleeping

I halved the Silenor tablet my doctor prescribed me for insomnia after the first dose made me feel like a zombie the next day. Even halving the dosage leaves me feeling drowsy and barely functional for several hours afterward, so it's not worth it to me.

1

Patient Review

10/15/2016

Silenor for Chronic Trouble Sleeping

This treatment was ineffective for me and made it harder to function the next day. I wouldn't recommend it to anyone with chronic insomnia.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about silenor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take for Silenor to kick in?

"After taking doxepin, you should limit your activities to those necessary to prepare for sleep. Doxepin works best when taken 3 hours after a meal and within 30 minutes of bedtime."

Answered by AI

What are the side effects of Silenor?

"trouble sleeping

Drowsiness, dizziness, stuffy nose, sneezing, sore throat, nausea, vomiting, diarrhea, constipation, loss of appetite, and trouble sleeping are all symptoms of the cold."

Answered by AI

Is Silenor a narcotic?

"The manufacturer of Silenor claims that it is a non-abusable option for insomnia relief and is not classified as a controlled substance by the DEA."

Answered by AI

Is Silenor a good sleeping pill?

"Doxepin is a medication used to treat insomnia. It is in a class of medications called tricyclic antidepressants. Doxepin works by slowing activity in the brain to allow sleep."

Answered by AI

Clinical Trials for Silenor

Image of Northwestern University in Evanston, United States.

Sleep and Dreaming Practices for Anxiety

18+
All Sexes
Evanston, IL

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods. This study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions. The primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions. Results from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being

Phase < 1
Waitlist Available

Northwestern University (+1 Sites)

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials
Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 70
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Healthy Minds smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials
Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials